Millennium Management
GTHX

Millennium Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Millennium Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13,700
Closed -$312K – 4714
2019
Q3 		$312K Buy
+13,700
New +$432K ﹤0.01% 3547

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management's GTHX Position: Q2 2024 in Review

Millennium Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 445,912 shares — an estimated $1.93M sold.

Millennium Management first reported a position in GTHX in Q2 2017 and held it in 20 quarters. The position peaked at $14.6M in Q3 2022. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Millennium Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Millennium Management sold 445,912 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1.93M.
  • Millennium Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 20 quarters.
  • Millennium Management's G1 Therapeutics, Inc. Common Stock position peaked at $14.6M in Q3 2022.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.